Hend Mohamed El Tayebi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hend Mohamed El Tayebi has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Reda A. Eissa
Department Of Surgery, Ain Shams University, Egypt
7 shared publicationsNada H. Hussein
Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Egypt
6 shared publicationsMonica Armanious
Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt
4 shared publicationsNada Sherif Amin
Clinical Pharmacology and Pharmacogenomics Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology German University in Cairo Cairo Egypt
4 shared publications- Aya A. Elkhodiry
Molecular Pharmacology Research Group, Department of Pharmacology, Toxicology and Clinical Pharmacy, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt
3 shared publications - Sawsan Elgohary
Clinical Pharmacology and Pharmacogenomics Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt
3 shared publications
Latest Publications
- Open Access
- 26 April 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102595
LncRNA AFAP1-AS1 mediates therapy-dependent expression of CCL5, CXCL10 and MMP9 in multiple sclerosis
- 26 April 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102595
Open AccessLncRNA AFAP1-AS1 mediates therapy-dependent expression of CCL5, CXCL10 and MMP9 in multiple sclerosis
- Open Access
- 31 December 2025
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 412, 578852
Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial
- 31 December 2025
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 412, 578852
Open AccessEfficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial
- 22 December 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 278, 156341
Unraveling ADC resistance in hematologic malignancies: Challenges and new frontiers
- 22 December 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 278, 156341
Unraveling ADC resistance in hematologic malignancies: Challenges and new frontiers
- Open Access
- 20 November 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 108
Exploring Neural Stem Cell Therapies as Innovative Treatments for Glioblastoma
Glioblastoma (GB) is among the most aggressive and treatment-resistant brain tumors, largely due to its heterogeneous tumor microenvironment (TME) and the protective nature of the blood–brain barrier (BBB). Recent advances have highlighted the therapeutic potential of neural stem cells (NSCs), which possess tumor-homing capabilities that enable them to selectively migrate toward and infiltrate GB sites. Engineered NSCs can deliver therapeutic agents, including oncolytic viruses, prodrug-converting enzymes, and genetic materials, offering targeted treatment while minimizing systemic toxicity. Preclinical studies have demonstrated NSCs' promise in enhancing drug delivery, modulating the TME, and promoting anti-tumor immune responses. However, translational hurdles persist, including tumor heterogeneity, species-specific immune responses, and challenges in ensuring long-term safety. Emerging strategies—such as genetic modification to improve tumor targeting and the incorporation of biomaterials to enhance retention—are under investigation. Integrating personalized medicine approaches may further optimize NSC-based therapies by tailoring treatment to individual patient profiles. While significant barriers remain, ongoing research may ultimately establish NSCs as a viable and effective platform for GB therapy. Graphical Abstract Engineered NSC for GB GB, an aggressive brain tumor, is being tackled with neural stem cells (NSCs) that are engineered to infiltrate tumor sites, showing potential to enhance drug delivery and modulate the tumor microenvironment for future personalized treatments. Despite the challenges, ongoing translational research actively addresses tumor heterogeneity.
- 20 November 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 108
Open AccessExploring Neural Stem Cell Therapies as Innovative Treatments for Glioblastoma
Glioblastoma (GB) is among the most aggressive and treatment-resistant brain tumors, largely due to its heterogeneous tumor microenvironment (TME) and the protective nature of the blood–brain barrier (BBB). Recent advances have highlighted the therapeutic potential of neural stem cells (NSCs), which possess tumor-homing capabilities that enable them to selectively migrate toward and infiltrate GB sites. Engineered NSCs can deliver therapeutic agents, including oncolytic viruses, prodrug-converting enzymes, and genetic materials, offering targeted treatment while minimizing systemic toxicity. Preclinical studies have demonstrated NSCs' promise in enhancing drug delivery, modulating the TME, and promoting anti-tumor immune responses. However, translational hurdles persist, including tumor heterogeneity, species-specific immune responses, and challenges in ensuring long-term safety. Emerging strategies—such as genetic modification to improve tumor targeting and the incorporation of biomaterials to enhance retention—are under investigation. Integrating personalized medicine approaches may further optimize NSC-based therapies by tailoring treatment to individual patient profiles. While significant barriers remain, ongoing research may ultimately establish NSCs as a viable and effective platform for GB therapy. Graphical Abstract Engineered NSC for GB GB, an aggressive brain tumor, is being tackled with neural stem cells (NSCs) that are engineered to infiltrate tumor sites, showing potential to enhance drug delivery and modulate the tumor microenvironment for future personalized treatments. Despite the challenges, ongoing translational research actively addresses tumor heterogeneity.
- Open Access
- 25 September 2024
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 26, e18
Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy
Recent development in immunotherapy for cancer treatment has substantiated to be more effective than most of the other treatments. Immunity is the first line of defence of the body; nevertheless, cancerous cells can manipulate immunity compartments to play several roles in tumour progression. Tumour-associated macrophages (TAMs), one of the most dominant components in the tumour microenvironment, are recognized as anti-tumour suppressors. Unfortunately, the complete behaviour of TAMs is still unclear and understudied. TAM density is directly correlated with the progression and poor prognosis of hepatocellular carcinoma (HCC), therefore studying TAMs from different points of view passing by all the factors that may affect its existence, polarization, functions and repolarization are of great importance. Different epigenetic regulations were reported to have a direct relation with both HCC and TAMs. Here, this review discusses different epigenetic regulations that can affect TAMs in HCC whether positively or negatively.
- 25 September 2024
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 26, e18
Open AccessEpigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy
Recent development in immunotherapy for cancer treatment has substantiated to be more effective than most of the other treatments. Immunity is the first line of defence of the body; nevertheless, cancerous cells can manipulate immunity compartments to play several roles in tumour progression. Tumour-associated macrophages (TAMs), one of the most dominant components in the tumour microenvironment, are recognized as anti-tumour suppressors. Unfortunately, the complete behaviour of TAMs is still unclear and understudied. TAM density is directly correlated with the progression and poor prognosis of hepatocellular carcinoma (HCC), therefore studying TAMs from different points of view passing by all the factors that may affect its existence, polarization, functions and repolarization are of great importance. Different epigenetic regulations were reported to have a direct relation with both HCC and TAMs. Here, this review discusses different epigenetic regulations that can affect TAMs in HCC whether positively or negatively.
- 5 August 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 54 (12) , e14297
When less is more: The association between the expression of polymorphic CYPs and AFB1‐induced HCC
Background: An individual’s genetic fingerprint is emerging as a pivotal predictor of numerous disease‐ and treatment‐related factors. Single nucleotide polymorphisms (SNPs) in drug‐metabolizing enzymes play key roles in an individual’s exposure to a malignancy‐associated risk, such as Aflatoxin B1 (AFB1)‐induced hepatocellular carcinoma (HCC).Aim: This study aimed at reviewing literature on the polymorphisms that exist in CYP enzymes and their possible link with susceptibility to AFB1‐induced HCC.Materials & Methods: A set of keywords associated with the study subject of interest was used to search the Google Scholar and the PubMed database. The last ten years’ worth of research projects were included in the results filter. The research involved HCC patients and any connection between polymorphic forms of CYP enzymes and their susceptibility to AFB1‐induced HCC, including older but significant data.Results: Variations in CYP1A2 and CYP3A4 were reported to impact the rate and magnitude of AFB1 bio‐activation, thus influencing an individual’s vulnerability to develop HCC. In HCC patients, the activity of CYP isoforms varies, where increased activity has been reported with CYP2C9, CYP2D6, and CYP2E1, while CYP1A2, CYP2C8, and CYP2C19 exhibit decreased activity. CYP2D6*10 frequency has been discovered to differ considerably in HCC patients. Rs2740574 (an upstream polymorphism in CYP3A4 as detected in CYP3A4*1B) and rs776746 (which affects CYP3A5 RNA splicing), both of which influence CYP3A expression, thus impacting the variability of AFB1‐epoxide adducts in HCC patients.Discussion: CYP1A2 is the primary enzyme accountable for the formation of harmful AFBO globally. CYP3A4, CYP3A5, CYP3A7, CYP2B7, and CYP3A3 are also implicated in the bio‐activation of AFB1 to mutagenic metabolites. It is thought that CYP3A4 is the protein that interacts with AFB1 metabolism the most.Conclusion: Polymorphic variants of CYP enzymes have a functional impact on the susceptibility to AFB1‐induced HCC. Outlining such variation and their implications may provide deeper insights into approaching HCC in a more personalized manner for guiding future risk‐assessment, diagnosis, and treatment.
- 5 August 2024
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 54 (12) , e14297
When less is more: The association between the expression of polymorphic CYPs and AFB1‐induced HCC
Background: An individual’s genetic fingerprint is emerging as a pivotal predictor of numerous disease‐ and treatment‐related factors. Single nucleotide polymorphisms (SNPs) in drug‐metabolizing enzymes play key roles in an individual’s exposure to a malignancy‐associated risk, such as Aflatoxin B1 (AFB1)‐induced hepatocellular carcinoma (HCC).Aim: This study aimed at reviewing literature on the polymorphisms that exist in CYP enzymes and their possible link with susceptibility to AFB1‐induced HCC.Materials & Methods: A set of keywords associated with the study subject of interest was used to search the Google Scholar and the PubMed database. The last ten years’ worth of research projects were included in the results filter. The research involved HCC patients and any connection between polymorphic forms of CYP enzymes and their susceptibility to AFB1‐induced HCC, including older but significant data.Results: Variations in CYP1A2 and CYP3A4 were reported to impact the rate and magnitude of AFB1 bio‐activation, thus influencing an individual’s vulnerability to develop HCC. In HCC patients, the activity of CYP isoforms varies, where increased activity has been reported with CYP2C9, CYP2D6, and CYP2E1, while CYP1A2, CYP2C8, and CYP2C19 exhibit decreased activity. CYP2D6*10 frequency has been discovered to differ considerably in HCC patients. Rs2740574 (an upstream polymorphism in CYP3A4 as detected in CYP3A4*1B) and rs776746 (which affects CYP3A5 RNA splicing), both of which influence CYP3A expression, thus impacting the variability of AFB1‐epoxide adducts in HCC patients.Discussion: CYP1A2 is the primary enzyme accountable for the formation of harmful AFBO globally. CYP3A4, CYP3A5, CYP3A7, CYP2B7, and CYP3A3 are also implicated in the bio‐activation of AFB1 to mutagenic metabolites. It is thought that CYP3A4 is the protein that interacts with AFB1 metabolism the most.Conclusion: Polymorphic variants of CYP enzymes have a functional impact on the susceptibility to AFB1‐induced HCC. Outlining such variation and their implications may provide deeper insights into approaching HCC in a more personalized manner for guiding future risk‐assessment, diagnosis, and treatment.
- 10 October 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 251, 154834
Corrigendum to “MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer” [Pathol. Res. Pract. 216 (2020) 153274]
- 10 October 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 251, 154834
Corrigendum to “MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer” [Pathol. Res. Pract. 216 (2020) 153274]
- 30 September 2023
- Published by Elsevier in Life Sciences
- Vol. 332, 122133
Corrigendum to “NEAT1: Culprit lncRNA linking PIG C, MSLN, and CD80 in triple-negative breast cancer” [Life Sci., volume 299 (2022) 120523]
- 30 September 2023
- Published by Elsevier in Life Sciences
- Vol. 332, 122133
Corrigendum to “NEAT1: Culprit lncRNA linking PIG C, MSLN, and CD80 in triple-negative breast cancer” [Life Sci., volume 299 (2022) 120523]
- Open Access
- 19 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14254
Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients
Breast cancer (BC) is not only a mass of malignant cells but also a systemic inflammatory disease. BC pro-tumorigenic inflammation has been shown to promote immune evasion and provoke BC progression. The NOD-like receptor (NLR) family pyrin domain-containing protein 3 (NLRP3) inflammasome is activated when pattern recognition receptors (PRRs) sense danger signals such as calreticulin (CALR) from damaged/dying cells, leading to the secretion of interleukin-1β (IL-1β). CALR is a novel BC biological marker, and its high levels are associated with advanced tumors. NLRP3 expression is strongly correlated with an elevated proliferative index Ki67, BC progression, metastasis, and recurrence in patients with hormone receptor-positive (HR+) and triple-negative BC (TNBC). Tumor-associated macrophages (TAMs) secrete high levels of IL-1β promoting endocrine resistance in HR+ BC. Recently, an immunosuppressive soluble form of programmed death ligand 1 (sPD-L1) has been identified as a novel prognostic biomarker in triple-negative breast cancer (TNBC) patients. Interestingly, IL-1β induces sPD-L1 release. BC Patients with elevated IL-1β and sPD-L1 levels show significantly short progression-free survival. For the first time, this study aims to investigate the inhibitory impact of thymoquinone (TQ) on CALR, the NLRP3 pathway and sPD-L1 in HR+ and TNBC. Blood samples were collected from 45 patients with BC. The effect of differing TQ concentrations for different durations on the expression of CALR, NLRP3 complex components and IL-1β as well as the protein levels of sPD-L1 and IL-1β were investigated in the peripheral blood mononuclear cells (PBMCs) and TAMs of TNBC and HR+ BC patients, respectively. The findings showed that TQ significantly downregulated the expression of CALR, NLRP3 components and IL-1β together with the protein levels of secreted IL-1β and sPD-L1. The current findings demonstrated novel immunomodulatory effects of TQ, highlighting its potential role not only as an excellent adjuvant but also as a possible immunotherapeutic agent in HR+ and TNBC patients.
- 19 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14254
Open AccessThymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients
Breast cancer (BC) is not only a mass of malignant cells but also a systemic inflammatory disease. BC pro-tumorigenic inflammation has been shown to promote immune evasion and provoke BC progression. The NOD-like receptor (NLR) family pyrin domain-containing protein 3 (NLRP3) inflammasome is activated when pattern recognition receptors (PRRs) sense danger signals such as calreticulin (CALR) from damaged/dying cells, leading to the secretion of interleukin-1β (IL-1β). CALR is a novel BC biological marker, and its high levels are associated with advanced tumors. NLRP3 expression is strongly correlated with an elevated proliferative index Ki67, BC progression, metastasis, and recurrence in patients with hormone receptor-positive (HR+) and triple-negative BC (TNBC). Tumor-associated macrophages (TAMs) secrete high levels of IL-1β promoting endocrine resistance in HR+ BC. Recently, an immunosuppressive soluble form of programmed death ligand 1 (sPD-L1) has been identified as a novel prognostic biomarker in triple-negative breast cancer (TNBC) patients. Interestingly, IL-1β induces sPD-L1 release. BC Patients with elevated IL-1β and sPD-L1 levels show significantly short progression-free survival. For the first time, this study aims to investigate the inhibitory impact of thymoquinone (TQ) on CALR, the NLRP3 pathway and sPD-L1 in HR+ and TNBC. Blood samples were collected from 45 patients with BC. The effect of differing TQ concentrations for different durations on the expression of CALR, NLRP3 complex components and IL-1β as well as the protein levels of sPD-L1 and IL-1β were investigated in the peripheral blood mononuclear cells (PBMCs) and TAMs of TNBC and HR+ BC patients, respectively. The findings showed that TQ significantly downregulated the expression of CALR, NLRP3 components and IL-1β together with the protein levels of secreted IL-1β and sPD-L1. The current findings demonstrated novel immunomodulatory effects of TQ, highlighting its potential role not only as an excellent adjuvant but also as a possible immunotherapeutic agent in HR+ and TNBC patients.
- Open Access
- 3 September 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (37) , 33242-33254
Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents
Blockade of the programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) immune checkpoint pathway is an efficient immunotherapeutic modality that provided significant advances in cancer treatment especially in solid tumors highly resistant to traditional therapy. Monoclonal antibodies (mAbs) and small-molecule inhibitors are the two main strategies used to block this axis with mAbs suffering from many limitations. Accordingly, the current alternative is the development of small-molecule PD-1/PD-L1 inhibitors. Here, we present a sequential virtual screening (VS) protocol involving pharmacophore screening followed by molecular docking for the discovery of novel PD-L1 inhibitors. The VS protocol resulted in the discovery of eight novel compounds. A 100 ns MD simulation showed two compounds, H4 and H6, exhibiting a stable binding mode at the PD-L1 dimer interface. Upon evaluation of their immunological activities, the two compounds induced higher cytokines levels (IL-2, IL-6, and INF-γ) relative to BMS-202, 72 h post treatment of PBMCs of HCC patients. Thus, the discovered hits represent potential leads for the development of novel classes targeting the PD-L1 receptor as anti-hepatocellular carcinoma agents.
- 3 September 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (37) , 33242-33254
Open AccessVirtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents
Blockade of the programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) immune checkpoint pathway is an efficient immunotherapeutic modality that provided significant advances in cancer treatment especially in solid tumors highly resistant to traditional therapy. Monoclonal antibodies (mAbs) and small-molecule inhibitors are the two main strategies used to block this axis with mAbs suffering from many limitations. Accordingly, the current alternative is the development of small-molecule PD-1/PD-L1 inhibitors. Here, we present a sequential virtual screening (VS) protocol involving pharmacophore screening followed by molecular docking for the discovery of novel PD-L1 inhibitors. The VS protocol resulted in the discovery of eight novel compounds. A 100 ns MD simulation showed two compounds, H4 and H6, exhibiting a stable binding mode at the PD-L1 dimer interface. Upon evaluation of their immunological activities, the two compounds induced higher cytokines levels (IL-2, IL-6, and INF-γ) relative to BMS-202, 72 h post treatment of PBMCs of HCC patients. Thus, the discovered hits represent potential leads for the development of novel classes targeting the PD-L1 receptor as anti-hepatocellular carcinoma agents.